avapro has been researched along with Hypotension in 11 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 9.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 5.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| " These effects of SR 47436 are consistent with good oral bioavailability and a slow elimination of the drug (t 1/2 approximately 20 h), and were accompanied by a sustained increase in plasma AII concentration." | 1.29 | A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. ( Cazaubon, C; Donat, F; Marchionni, D; Nisato, D; Roccon, A; Segondy, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, P | 1 |
| Luo, Y | 1 |
| Zhang, J | 1 |
| Liu, H | 1 |
| Chen, J | 1 |
| Wang, J | 1 |
| Dong, G | 1 |
| Ge, M | 1 |
| Peters, CD | 1 |
| Kjaergaard, KD | 1 |
| Jensen, JD | 1 |
| Christensen, KL | 1 |
| Strandhave, C | 1 |
| Tietze, IN | 1 |
| Novosel, MK | 1 |
| Bibby, BM | 1 |
| Jespersen, B | 1 |
| Lewin, AJ | 1 |
| Weir, MR | 1 |
| Schillaci, G | 1 |
| Pucci, G | 1 |
| Pirro, M | 1 |
| Venon, WD | 1 |
| Baronio, M | 1 |
| Leone, N | 1 |
| Rolfo, E | 1 |
| Fadda, M | 1 |
| Barletti, C | 1 |
| Todros, L | 1 |
| Saracco, G | 1 |
| Rizzetto, M | 1 |
| Nielsen, EW | 1 |
| McNamee, JJ | 1 |
| Trainor, D | 1 |
| Michalek, P | 1 |
| Roccon, A | 1 |
| Marchionni, D | 1 |
| Donat, F | 1 |
| Segondy, D | 1 |
| Cazaubon, C | 1 |
| Nisato, D | 1 |
| Brabant, SM | 1 |
| Eyraud, D | 1 |
| Bertrand, M | 1 |
| Coriat, P | 1 |
| Schepke, M | 1 |
| Werner, E | 1 |
| Biecker, E | 1 |
| Schiedermaier, P | 1 |
| Heller, J | 1 |
| Neef, M | 1 |
| Stoffel-Wagner, B | 1 |
| Hofer, U | 1 |
| Caselmann, WH | 1 |
| Sauerbruch, T | 1 |
| Marin-Castaño, ME | 1 |
| Schanstra, JP | 1 |
| Neau, E | 1 |
| Praddaude, F | 1 |
| Pecher, C | 1 |
| Ader, JL | 1 |
| Girolami, JP | 1 |
| Bascands, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study[NCT00791830] | Phase 3 | 82 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for avapro and Hypotension
6 other studies available for avapro and Hypotension
| Article | Year |
|---|---|
Irbesartan for heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Heart Failure; Humans; | 2009 |
Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values.
Topics: Angioedema; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Female; Humans; | 2005 |
Terlipressin for refractory hypotension following angiotensin-II receptor antagonist overdose.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Overdose; Female; Humans; Hypotens | 2006 |
A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.
Topics: Administration, Oral; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animal | 1994 |
Refractory hypotension after induction of anesthesia in a patient chronically treated with angiotensin receptor antagonists.
Topics: Adrenergic Agents; Aged; Anesthesia, Intravenous; Anesthetics, Intravenous; Angiotensin Receptor Ant | 1999 |
Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 2002 |